Caplin Point Laboratories Share Price
2768.40-76.60 (-2.69%)
+28.11% past 1 Year
News
Caplin Point subsidiary Caplin Steriles receives USFDA Form 483 with 10 observations
Equity
CAPLIPOINT
Caplin Point Lab reports higher Q1 EBITDA with margin expansion
Equity
CAPLIPOINT
Caplin Point Lab reports 26 percent rise in US market Q1 FY27 revenue
Equity
CAPLIPOINT
Caplin Point Lab reports higher Q1 revenue of Rs 610 crores
Equity
CAPLIPOINT
Caplin Point Lab posts higher Q1 net profit at Rs 177 crore year on year
Equity
CAPLIPOINT
Caplin Point Laboratories’ arm gets USFDA approval for Foscarnet Sodium injection
Equity
CAPLIPOINT
Caplin Point Lab - Quaterly Results
Equity
CAPLIPOINT
Caplin Point Laboratories informs about outcome of board meeting
Equity
CAPLIPOINT
Caplin Point Laboratories Plans Expansion into Regulated Markets Including Canada, Australia, MENA, Russia/CIS, Mexico, Brazil
Equity
CAPLIPOINT
Caplin Point Lab reports Profit after tax of 109.50 Crores, in the March 2026 quarter
Equity
CAPLIPOINT
Caplin Point Laboratories Q4 EBITDA Rises 21% YoY to Rs 204 Crores, Margin Contracts to 34.03%
Equity
CAPLIPOINT
Caplin Point Labs Q4 FY26 Revenue Growth at 19.5% YoY to Rs 600 Crores
Equity
CAPLIPOINT
Caplin Point Labs Q4 Consolidated Net Profit Rises 17.2% YoY to Rs 170 Crores
Equity
CAPLIPOINT
Caplin Point gains as its arm gets USFDA’s approval for Calcium Gluconate Injection
Equity
CAPLIPOINT
Caplin Point’s arm gets USFDA’s approval for Calcium Gluconate Injection
Equity
CAPLIPOINT
Caplin Point Lab's Caplin Steriles Secures USFDA Approval for Calcium Gluconate Injection.
Equity
CAPLIPOINT
Caplin Point’s arm gets USFDA’s final nod for Potassium Phosphates Injection
Equity
CAPLIPOINT
Caplin Point Laboratories informs about press release
Equity
CAPLIPOINT
Caplin Point Laboratories Subsidiary Caplin Steriles Secures USFDA Approval for Potassium Phosphates Injection.
Equity
CAPLIPOINT
Caplin Point’s arm secures USFDA’s final approval for Desmopressin Acetate Injection
Equity
CAPLIPOINT